SEOUL-VIOSYS/TYPHON
27.6.2022 10:47:08 CEST | Business Wire | Press release
Seoul Viosys (KOSDAQ: 092190), a company specializing in optical semiconductors, announced that the ‘Violeds’ technology was supplied to Typhon Treatment Systems Ltd. , a British water treatment company, and applied to the UK's Cumbria water purification plant with a daily water purification capacity of 30,000 cubic meters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005267/en/
UV lamp sterilization using mercury has been used in water purification facilities for the past several decades, and despite the restrictions on mercury products by the Minamata Convention, it was difficult to replace the sterilization performance, so it was subject to special permission. However, Violeds uses LEDs as a UV source, so it does not use mercury and reduces the amount of chemicals used for sterilization, thereby reducing the occurrence of environmental problems. In addition, an energy-efficient operation is possible through easy automatic control according to water usage thereby reducing operating costs compared to facilities using existing UV lamps. In particular, the expected effect is large in facilities such as water purification plants that need to be operated for a long time.
Typhon's BIO-310 UV LED Reactor, installed in the Cumbria water purification plant in the UK with Violeds applied, has an optimal design for the arrangement and operation of UV LEDs, and can process 30,000 cubic meters of water per day. BIO-310 was selected as a winner in the water supply field at Aquatech Amsterdam 2021, the largest water treatment exhibition in Europe and the most influential one in the world.
According to a Typhon official, the UV application market is around USD 950 million out of the USD 400 billion water treatment market per year. UV technology can protect water from Cryptosporidium, which is difficult to sterilize with chlorine, so it is expected to be expanded to water purification plants around the world in the coming few years when the improvements in efficiency of the UV LEDs and cost decrease will make even more attractive the return on investment. Within the next 2 years, we see the tipping point where LED power/efficiency development changes the scenario from ‘Why use LED’ to ‘Why not use LED’.
Oliver Schafer, EVP Seoul Viosys & Seoul Semiconductor Sales Division, underlines: “In order to prevent water quality accidents due to occurrence of algae and larvae in tap water every year, our proprietary Violeds technology provides fundamental advantages compared to legacy mercury lamp usage and the resulting environmental damage effects. Our research team is spurring R&D of Violeds technology so that you can trust and drink it in an environmentally friendly way.”
About Typhon Treatment Systems Ltd.
In 2013, Typhon’s founders, Dr. Matthew Simpson and Peter McNulty were working together on an off-grid municipal scale water project in Nigeria. The need for a sustainable and simplistic solution inspired them to investigate the possibility of using Mercury Free high flow LED ultraviolet (UV) water treatment equipment. None existed, and no existing UV water treatment equipment supplier would build one for them. In 2014, Typhon Treatment Systems was formed to create it. We now deliver a UV LED solution that is 100% mercury-free, reduces maintenance, and dramatically reduces ancillary infrastructure (Glass/Mercury traps).
At this time we focus on two main applications leveraging UVC LEDs:
- Biological disinfection for inactivation of pathogens
- Photochemical oxidation processes for removal of chemical water contaminants
Typhon’s USEPA UVDGM validated BIO-310 reactor is the only Municipal scale UV LED system available today. Typhon has collaborated with United Utilities to deliver the world’s largest UV LED for drinking water disinfection installation, with the capacity to treat nearly 30,000m3 /day.
https://www.typhontreatment.com/
Media contact:
Mike Hemingway
mhemingway@typhontreatment.com
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 6,800 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005267/en/
Link:
Social Media:
https://www.facebook.com/violedsTechnologykorea/?brand_redir=1698430287094913
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom